| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 15.05.
| Endocyte and Oncothyreon Look to Benefit From Enhancements to U.S. Patent System / Five Star Equities Provides Stock Research on Endocyte and Oncothyreon | | 26 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 05/15/12 -- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent...
Mehr lesen zu:
Endocyte and Oncothyreon Look to Benefit From Enhancements to U.S. Patent System / Five Star Equities Provides Stock Research on Endocyte and Oncothyreon | |
| 10.05.
| Oncothyreon to Present at Bank of America Merrill Lynch 2012 Health Care Conference | | 8 | PR Newswire |
| SEATTLE, WA, May 10, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY)
announced today that Robert Kirkman, M.D., President and Chief
Executive Officer, will be presenting at the Bank of America...
Mehr lesen zu:
Oncothyreon to Present at Bank of America Merrill Lynch 2012 Health Care Conference | |
| 07.05.
| Oncothyreon Inc. - 10-Q, Quarterly Report | | - | SEC Filings |
| 07.05.
| Oncothyreon Reports First Quarter 2012 Financial Results | | 27 | PR Newswire |
| Company to Hold Conference Call at 4:30 p.m. EDT Today
SEATTLE, May 7, 2012 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today
reported financial results for the first quarter ending March...
Mehr lesen zu:
Oncothyreon Reports First Quarter 2012 Financial Results | |
| 30.04.
| Oncothyreon Announces First Quarter 2012 Financial Results Conference Call | | 8 | PR Newswire |
| SEATTLE, April 30, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced that it will conduct a conference call to discuss its first
quarter 2012 financial results and provide a review...
Mehr lesen zu:
Oncothyreon Announces First Quarter 2012 Financial Results Conference Call | |
| 17.04.
| Possible Bullish Inside Day Candle Pattern Detected for Oncothyreon | | - | SmarTrend |
| 13.04.
| Oncothyreon to Present at Future Leaders in the Biotech Industry Conference | | 23 | PR Newswire |
| SEATTLE, April 13, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY)
announced today that Robert Kirkman, M.D., President and Chief
Executive Officer, will be presenting at the 19th Annual Future...
Mehr lesen zu:
Oncothyreon to Present at Future Leaders in the Biotech Industry Conference | |
| 03.04.
| Oncothyreon (ONTY) Closes 13.5M Common Offering at $4/Share | | 1 | StreetInsider.com |
| 03.04.
| Oncothyreon Announces Exercise of Underwriters' Over-Allotment Option and Closing of $54.1 million Public Offering of Common Stock | | 21 | PR Newswire |
| SEATTLE, WA, April 3, 2012 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today
announced that it has closed the previously announced underwritten
public offering of 13,512,500 shares of its common...
Mehr lesen zu:
Oncothyreon Announces Exercise of Underwriters' Over-Allotment Option and Closing of $54.1 million Public Offering of Common Stock | |
| 29.03.
| Oncothyreon Prices $47.0 Million Public Offering of Common Stock at $4.00 per Share | | 2 | Benzinga.com |
| 29.03.
| Oncothyreon Prices $47.0 Million Public Offering of Common Stock | | 18 | PR Newswire |
| SEATTLE, March 29, 2012 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today
announced that it has priced an underwritten public offering of
11,750,000 shares of its common stock at a price to...
Mehr lesen zu:
Oncothyreon Prices $47.0 Million Public Offering of Common Stock | |
| 28.03.
| Oncothyreon Announces Proposed Public Offering of Common Stock | | 27 | PR Newswire |
| SEATTLE, WA, March 28, 2012 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY)
today announced its intention to offer, subject to market and other
conditions, shares of its common stock in an underwritten...
Mehr lesen zu:
Oncothyreon Announces Proposed Public Offering of Common Stock | |
| 14.03.
| Oncothyreon (ONTY) Enrolls First Patient in ONT-10 Phase 1 | | 1 | StreetInsider.com |
| 14.03.
| Oncothyreon Initiates Phase 1 Trial of Therapeutic Vaccine Product Candidate ONT-10 | | 20 | PR Newswire |
| SEATTLE, March 14, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced that the first patient has been enrolled in a Phase 1 trial
of ONT-10, a therapeutic vaccine directed at MUC1....
Mehr lesen zu:
Oncothyreon Initiates Phase 1 Trial of Therapeutic Vaccine Product Candidate ONT-10 | |
| 12.03.
| Biotech Industry Growing Domestically and Abroad -- Oncothyreon and AEterna Zentaris Poised for Growth / The Paragon Report Provides Equity Research on Oncothyreon & AEterna Zentaris | | 49 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 03/12/12 -- The biotechnology industry has been on an impressive run this year as companies -- both large and small -- show impressive growth. The iShares Nasdaq Biotechnology...
Mehr lesen zu:
Biotech Industry Growing Domestically and Abroad -- Oncothyreon and AEterna Zentaris Poised for Growth / The Paragon Report Provides Equity Research on Oncothyreon & AEterna Zentaris | |
| 06.03.
| Oncothyreon Reports Full Year and Fourth Quarter 2011 Financial Results | | 27 | PR Newswire |
| Company to Hold Conference Call at 4:30 p.m. Eastern Today
SEATTLE, WA, March 6, 2012 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today
reported financial results for the year and quarter ending...
Mehr lesen zu:
Oncothyreon Reports Full Year and Fourth Quarter 2011 Financial Results | |
| 28.02.
| Oncothyreon Announces Full Year and Fourth Quarter 2011 Financial Results Conference Call | | 32 | PR Newswire |
| SEATTLE, Feb. 28, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced that it will conduct a conference call to discuss its full
year and fourth quarter 2011 financial results and...
Mehr lesen zu:
Oncothyreon Announces Full Year and Fourth Quarter 2011 Financial Results Conference Call | |
| 28.02.
| Oncothyreon Announces Presentations at Upcoming Investment Conferences in March 2012 | | 9 | PR Newswire |
| SEATTLE, Feb. 28, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced
today that Robert Kirkman, M.D., President and Chief Executive Officer,
will be presenting at the following upcoming...
Mehr lesen zu:
Oncothyreon Announces Presentations at Upcoming Investment Conferences in March 2012 | |
| 23.02.
| Investor Optimism in Biotech Skyrockets - Cardium Therapeutics and Oncothyreon on the Upswing / The Paragon Report Provides Equity Research on Cardium Therapeutics & Oncothyreon | | 27 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 02/23/12 -- Biotechnology stocks have performed well of late as companies from across the globe earn more investments. According to a report from Boulder-based data...
Mehr lesen zu:
Investor Optimism in Biotech Skyrockets - Cardium Therapeutics and Oncothyreon on the Upswing / The Paragon Report Provides Equity Research on Cardium Therapeutics & Oncothyreon | |
| 07.02.
| Oncothyreon Announces Presentations at Upcoming Investment Conferences in February 2012 | | 24 | PR Newswire |
| SEATTLE, WA, Feb. 7, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY)
announced today that Robert Kirkman, M.D., President and Chief
Executive Officer, will be presenting at the following upcoming
...
Mehr lesen zu:
Oncothyreon Announces Presentations at Upcoming Investment Conferences in February 2012 | |
